Mucus polymer concentration and in vivo adaptation converge to define the antibiotic response of Pseudomonas aeruginosa during chronic lung infection

Matthew A. Greenwald,Suzanne L. Meinig,Lucas M. Plott,Cristian Roca,Matthew G. Higgs,Nicholas P. Vitko,Matthew R. Markovetz,Kaitlyn R. Rouillard,Jerome Carpenter,Mehmet Kesimer,David B. Hill,Jonathan C. Schisler,Matthew C. Wolfgang

DOI: https://doi.org/10.1128/mbio.03451-23

IF: 6.4

2024-04-24

mBio

Abstract:ABSTRACT The airway milieu of individuals with muco-obstructive airway diseases (MADs) is defined by the accumulation of dehydrated mucus due to hyperabsorption of airway surface liquid and defective mucociliary clearance. Pathological mucus becomes progressively more viscous with age and disease severity due to the concentration and overproduction of mucin and accumulation of host-derived extracellular DNA (eDNA). Respiratory mucus of MADs provides a niche for recurrent and persistent colonization by respiratory pathogens, including Pseudomonas aeruginosa , which is responsible for the majority of morbidity and mortality in MADs. Despite high concentration inhaled antibiotic therapies and the absence of antibiotic resistance, antipseudomonal treatment failure in MADs remains a significant clinical challenge. Understanding the drivers of antibiotic tolerance is essential for developing more effective treatments that eradicate persistent infections. The complex and dynamic environment of diseased airways makes it difficult to model antibiotic efficacy in vitro . We aimed to understand how mucin and eDNA concentrations, the two dominant polymers in respiratory mucus, alter the antibiotic tolerance of P. aeruginosa . Our results demonstrate that polymer concentration and molecular weight affect P. aeruginosa survival post antibiotic challenge. Polymer-driven antibiotic tolerance was not explicitly associated with reduced antibiotic diffusion. Lastly, we established a robust and standardized in vitro model for recapitulating the ex vivo antibiotic tolerance of P. aeruginosa observed in expectorated sputum across age, underlying MAD etiology, and disease severity, which revealed the inherent variability in intrinsic antibiotic tolerance of host-evolved P. aeruginosa populations. IMPORTANCE Antibiotic treatment failure in Pseudomonas aeruginosa chronic lung infections is associated with increased morbidity and mortality, illustrating the clinical challenge of bacterial infection control. Understanding the underlying infection environment, as well as the host and bacterial factors driving antibiotic tolerance and the ability to accurately recapitulate these factors in vitro , is crucial for improving antibiotic treatment outcomes. Here, we demonstrate that increasing concentration and molecular weight of mucin and host eDNA drive increased antibiotic tolerance to tobramycin. Through systematic testing and modeling, we identified a biologically relevant in vitro condition that recapitulates antibiotic tolerance observed in ex vivo treated sputum. Ultimately, this study revealed a dominant effect of in vivo evolved bacterial populations in defining inter-subject ex vivo antibiotic tolerance and establishes a robust and translatable in vitro model for therapeutic development.

microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the antibiotic tolerance of Pseudomonas aeruginosa in chronic lung infections. Specifically, the study focuses on how high - concentrations of mucin and host - derived extracellular DNA (eDNA) affect the tolerance of Pseudomonas aeruginosa to commonly used antibiotics (such as tobramycin) in the respiratory tract environment of patients with muco - obstructive airway diseases (MADs). Although these patients receive high - dose inhaled antibiotic therapy and the bacteria do not show resistance, treatment failures still occur frequently. Therefore, understanding how these environmental factors affect the efficacy of antibiotics is crucial for the development of more effective treatment methods.

The main objectives of the study include:
1. To explore how different concentrations of mucin and eDNA change the antibiotic tolerance of Pseudomonas aeruginosa.
2. To determine the effects of polymer concentration and molecular weight on the survival of Pseudomonas aeruginosa.
3. To establish an in vitro model that can simulate in vivo antibiotic tolerance in order to better study and predict clinical treatment effects.
4. To evaluate whether drugs that reduce or degrade mucin and eDNA can improve the efficacy of antibiotics.

Through these studies, the authors hope to reveal the main factors leading to antibiotic tolerance and provide a scientific basis for the development of new treatment strategies.